Doutor Nichires Holdings Co., Ltd. (3087) AI Stock Analysis

• Market Cap: ¥118.68B
• Dividend Yield: 1.86%
• Average Volume (3M): 145.79K
• Price to Earnings (P/E): 17.1
• Beta (1Y): 0.33
• Revenue Growth: 5.83%
• EPS Growth: 25.67%
• Country: JP
• Employees: 2,765
• Sector: Consumer Cyclical
• Sector Strength: 57
• Industry: Restaurants
• EPS (TTM): 24.96
• Shares Outstanding: 45,609,760
• 10 Day Avg. Volume: 123,830
• 30 Day Avg. Volume: 145,786
• PEG Ratio: 0.13
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -373.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 80 Outperform
• Price Target: ―

Doutor Nichires Holdings Co., Ltd. shows strong financial health with impressive revenue growth and profitability, low leverage, and healthy cash flow. Technical indicators suggest positive momentum, while the valuation is reasonable, supporting a favorable overall outlook.

Doutor Nichires Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Doutor Nichires Holdings Co., Ltd. is a prominent Japanese company operating in the food and beverage industry, primarily known for its cafe and restaurant businesses. The company operates a wide range of brands, including the well-known Doutor Coffee chain, which offers a variety of coffee beverages, sandwiches, and light meals. Doutor Nichires Holdings also engages in the production and distribution of coffee beans, bakery products, and other food items, catering to diverse consumer preferences across its domestic and international markets.

How the Company Makes Money

Doutor Nichires Holdings Co., Ltd. generates revenue through multiple streams, primarily driven by its retail operations, including its widespread network of cafe and restaurant locations under various brand names. The company earns income from the sale of coffee beverages, food items, and other complementary products in these outlets. Additionally, Doutor Nichires Holdings benefits from its coffee bean production and distribution business, supplying to both its own cafes and external clients. Strategic partnerships and franchise agreements also contribute to its revenue, allowing the company to expand its market presence both domestically and internationally. These diversified operations and revenue streams underpin the company's financial performance and growth.

Doutor Nichires Holdings Co., Ltd. Financial Statement Overview

Summary

Doutor Nichires Holdings has strong revenue growth and profitability, supported by a robust balance sheet with low leverage. Cash flow metrics are healthy, indicating good cash generation and a positive outlook.

Income Statement

Doutor Nichires Holdings Co., Ltd. has demonstrated strong revenue growth over the past years, with a notable recovery from past losses. The company's gross and net profit margins have improved significantly in recent years, reflecting effective cost management and increased efficiency. The EBIT and EBITDA margins have also shown positive trends, indicating robust operational performance.

Balance Sheet

The company maintains a strong financial position with a low debt-to-equity ratio, reflecting prudent financial management and low leverage risk. The equity ratio indicates a solid capital structure with substantial shareholder equity backing the company's assets. The return on equity has improved, showcasing enhanced profitability and efficient use of equity capital.

Cash Flow

Doutor Nichires Holdings has consistently generated positive operating cash flows, which have supported its investment activities and capital expenditures. The free cash flow growth rate is strong, suggesting healthy cash generation and potential for reinvestment or shareholder returns. The operating cash flow to net income ratio reflects a robust cash conversion cycle.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
146.82B	148.82B	140.63B	126.86B	109.36B	96.14B
	Gross Profit
88.75B	89.62B	84.19B	74.77B	64.31B	55.77B
	EBIT
9.55B	9.60B	7.32B	2.97B	-1.78B	-4.32B
	EBITDA
11.37B	13.94B	11.72B	6.88B	2.40B	-4.40B
	Net Income Common Stockholders
6.30B	6.88B	5.49B	3.43B	1.22B	-10.98B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
36.88B	38.99B	35.80B	32.22B	34.55B	26.31B
	Total Assets
134.22B	134.23B	127.79B	121.04B	118.23B	115.25B
	Total Debt
2.18B	2.11B	2.77B	1.71B	1.54B	1.31B
	Net Debt
-34.70B	-36.88B	-33.02B	-30.51B	-33.01B	-25.00B
	Total Liabilities
30.74B	29.88B	28.32B	24.75B	24.12B	21.25B
	Stockholders Equity
103.14B	104.00B	99.15B	96.01B	93.86B	93.78B
Cash Flow		Free Cash Flow
0.00	6.49B	6.87B	-221.00M	10.22B	-8.06B
	Operating Cash Flow
0.00	12.35B	11.79B	5.17B	14.64B	-2.88B
	Investing Cash Flow
0.00	-6.23B	-4.90B	-5.59B	-4.93B	-5.95B
	Financing Cash Flow
0.00	-2.93B	-3.37B	-1.98B	-1.50B	-2.15B

Doutor Nichires Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2644.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3087, the sentiment is Positive. The current price of 2644 is below the 20-day moving average (MA) of 2666.05, below the 50-day MA of 2645.78, and above the 200-day MA of 2375.85, indicating a bullish trend. The MACD of 11.12 indicates Positive momentum. The RSI at 54.65 is Neutral, neither overbought nor oversold. The STOCH value of 40.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3087.

Doutor Nichires Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3087	80 Outperform	¥118.68B	17.10		1.86%	5.83%	25.67%
7630	73 Outperform	¥142.06B	44.77		1.80%	10.64%	18.07%
2695	69 Neutral	¥130.87B	106.37		0.61%	4.82%	-79.12%
8153	69 Neutral	¥115.01B	36.53		0.80%	3.36%	22.37%
Sector *	62 Neutral	$6.76B	11.07	2.80%	6.34%	2.68%	-24.87%
9887	56 Neutral	¥108.81B	49.80		0.42%	20.85%	-25.02%
7412	49 Neutral	¥125.13B	237.58		―	-3.98%	―

Doutor Nichires Holdings Co., Ltd. Corporate Events

Doutor Nichires Holdings Initiates Treasury Share Disposal for Director Incentives

Doutor Nichires Holdings Co., Ltd. has announced the disposal of treasury shares as part of its Restricted Stock Compensation Plan, aimed at incentivizing directors to enhance corporate and shareholder value. This move is expected to strengthen the alignment of directors’ interests with those of shareholders, potentially impacting the company’s long-term market positioning positively.

Doutor Nichires Holdings Announces Treasury Share Purchase

Doutor Nichires Holdings Co., Ltd. announced the purchase of 811,000 treasury shares at a cost of ¥2,214,532,400 between April 15 and April 30, 2025, as part of a broader plan approved by the Board of Directors to acquire up to 3.5 million shares. This strategic move, executed on the Tokyo Stock Exchange, is expected to enhance shareholder value and optimize the company’s capital structure.

Doutor Nichires Announces Director Change

Doutor Nichires Holdings Co., Ltd. has announced a change in its board of directors, with Managing Director Yasuyuki Tenma set to retire on May 27, 2025. This change in leadership could influence the company’s strategic direction and operational focus, impacting stakeholders and potentially altering its market positioning.

Doutor Nichires Holdings Announces Treasury Share Acquisition

Doutor Nichires Holdings Co., Ltd. announced its decision to acquire up to 3.5 million of its own shares, representing 7.98% of its total issued shares, as part of a flexible capital policy and shareholder return strategy. This move is expected to enhance the company’s financial flexibility and potentially increase shareholder value.

Doutor Nichires Increases Year-End Dividend Amid Strong Performance

Doutor Nichires Holdings Co., Ltd. has announced an increase in its year-end dividend to 27 yen per share, reflecting strong sales performance and net income exceeding expectations post-COVID-19 recovery. This decision aligns with the company’s policy of maintaining a payout ratio of 30% to 40%, resulting in an annual dividend of 50 yen, a significant increase from the previous year.

Doutor Nichires Holdings Reports Strong Financial Growth for FY2025

Doutor Nichires Holdings Co., Ltd. reported a positive financial performance for the fiscal year ending February 28, 2025, with net sales increasing by 5.8% and operating profit rising by 31.1% compared to the previous year. The company also announced a forecast for continued growth in the upcoming fiscal year, with expected increases in net sales and profits, indicating a strong market position and potential benefits for stakeholders.